StockData

KORU Medical Systems vs TriSalus Life Sciences

KRMD and TLSI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRMD and TLSI compare

KORU Medical Systems and TriSalus Life Sciences are about the same size, with market caps of $161M and $141M.

TriSalus Life Sciences grew revenue faster over the last twelve months (25.2% versus 22.4% for KORU Medical Systems).

KORU Medical Systems keeps more of each dollar of sales as profit, with a net margin of −4.0% compared with −62.6% at TriSalus Life Sciences.

KORU Medical Systems scores higher on the StockData Score (12 against 5 for TriSalus Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRMDTLSI
Size and price
Market cap$161M$141M
Share price$3.49$2.29
Change, 1 year−19.2%−49.7%
Change, 5 years−4.4%−77.0%
Beta (5Y)1.092.29
Employees73102
StockData Score
Total score12 (better)5
Valuation score00
Growth score33
Performance score3 (better)1
Health score6 (better)1
Dividend score00
Valuation
P/S3.6×3.1× (better)
P/B8.9× (better)21.6×
P/FCF207×–
FCF yield0.48% (better)−16.5%
Fair value$2.67–
Margin of safety−30.9%–
Growth
Revenue growth (TTM)22.4%25.2% (better)
Revenue growth, 5Y average11.2%–
Profitability
Gross margin62.4%85.8% (better)
Operating margin−3.7% (better)−67.7%
Net margin−4.0% (better)−62.6%
FCF margin1.7% (better)−51.6%
Return on equity−10.5%–
Return on invested capital−14.3%–
Financial health
Debt / equity0.005.05 (better)
Interest coverage–−5.2×
Current ratio2.725.35 (better)
Altman Z-score10.07 (better)−6.02
Piotroski F-score5 (better)3
Dividends and buybacks
Buyback yield–−31.3%
Shareholder yield0.00% (better)−31.3%
Ownership
Held by institutions44.5%38.6%
Held by insiders17.6%29.7%
Insider net buying, 12 months$1.6M$3.6M (better)
Short interest, % of float2.3%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.